ESR1 and breast carcinoma: Regarding other signaling pathways, in a recent study of in vitro and in vivo models of estrogen receptor-positive (ER+) breast cancer, it was reported that the canonical activation of the NFκB pathway promoted a dormant, metastatic phenotype in ER+ breast cancer [51].